An observational study in Cancer Pain, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-04.
Sponsored by Hospices Civils de Lyon · Observational
The methadone is an useful opioid for the cancer pain treatment, mostly used in second or last line during the opioid rotation. The Methadone had an anti-MNDA effect, and clinicians agree that the methadone could have an effect in neuropathic cancer pain. During a previous study the investigators find that the pain was still improving after the week 2, but they had only a small number of patients still included at this stage and they cannot conclude.
The investigators decide to follow up systematically all the patients undergoing a methadone treatment for cancer pain, at day 28, to study the hypothesis about the long-term pain improvement.
338 studies on the registry are indexed under Cancer Pain; 71 are open to participants now.
This study's planned enrollment of 50 is below the median of 140 across 68 observational studies indexed under Cancer Pain.
Browse Cancer Pain studies →Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients undergoing a methadone treatment for cancer pain
Exclusion Criteria:
Difference between EVA pain score at Day 28 and Day 0
long-term effects of methadone for cancer pain
Time frame: pain score measure at Day 0 and Day 28
Change in score of neuropathic pain intensity NPSI
Time frame: Day 0 and Day 28
Change in depression and anxiety score HADS
Time frame: Day 0 and Day 28
Change in quality of life score QOL C30
Time frame: Day 0 and Day 28
Side effect record
Time frame: up to Day 28
This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospices Civils de Lyon